Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Checkpoint inhibitor induced colitis and arthritis – tocilizumab
2018-002595-41Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Colitis, immune checkpoint inhibitor-associated arthritis (ICI-IA) and diarrhea, sponsored by Herlev & Gentofte Hospital. Primary endpoint: Clinical improvement of immune-related adverse events. Started Jul 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
Colitisimmune checkpoint inhibitor-associated arthritis (ICI-IA)diarrhea
Beyond the preview
Go deeper on 2018-002595-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002595-41.